Remarkable progress has been made in curing a significant number of disseminated cancers, but at times the pace has seemed discouragingly slow. When I look back at both the successes and failures, and relate them to current concepts, I cannot help but wonder if the rate of future progress might be accelerated by application of basic tenets of the 40-year-old somatic mutation theory. By this I mean serious consideration of the implications of this theory in interpretation of available data and in the design of future therapeutic regimens.
No takes yet. Share an insight, caveat, or question.
Howard E. Skipper (1983) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: